Repligen Corporation

NASDAQ RGEN

Download Data

Repligen Corporation Research and Development (R&D) Expenses for the year ending December 31, 2023: USD 42.61 M

Repligen Corporation Research and Development (R&D) Expenses is USD 42.61 M for the year ending December 31, 2023, a -3.03% change year over year. Research and Development (R&D) Expenses consist of the costs associated with the development of new products, technologies, or improvements to existing products.
  • Repligen Corporation Research and Development (R&D) Expenses for the year ending December 31, 2022 was USD 43.94 M, a 28.19% change year over year.
  • Repligen Corporation Research and Development (R&D) Expenses for the year ending December 31, 2021 was USD 34.27 M, a 69.82% change year over year.
  • Repligen Corporation Research and Development (R&D) Expenses for the year ending December 31, 2020 was USD 20.18 M, a 3.76% change year over year.
  • Repligen Corporation Research and Development (R&D) Expenses for the year ending December 31, 2019 was USD 19.45 M, a 23.35% change year over year.
NASDAQ: RGEN

Repligen Corporation

CEO Mr. Anthony J. Hunt
IPO Date March 26, 1990
Location United States
Headquarters Building 1, Waltham, MA, United States, 02453
Employees 1,783
Sector Healthcare
Industry Medical instruments & supplies
Description

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

Similar companies

BDX

Becton Dickinson and Company

NA

NA

HOLX

Hologic Inc

NA

NA

ANGO

AngioDynamics Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email